|Mr. Robert B. Jones||CEO, Pres & Director||273k||N/A||1959|
|Mr. Peter A. Clemens||Sr. VP, CFO & Sec.||220k||N/A||1953|
|Dr. Albert W. Brzeczko||VP of Pharmaceutical Sciences of Acura Pharmaceutical Technologies, Inc.||257k||N/A||1957|
|Mr. James F. Emigh||VP of Corp. Devel.||N/A||N/A||1956|
|Mr. Robert A. Seiser Ph.D.||VP, Treasurer & Corp. Controller||N/A||N/A||1964|
Acura Pharmaceuticals, Inc., a specialty pharmaceutical company, engages in the research, development, and commercialization of technologies and products to address safe use of medications in the United States. It offers Oxaydo tablets, a Schedule II narcotic indicated for the management of acute and chronic moderate to severe pain; and Nexafed products, which are pseudoephedrine and acetaminophen tablets that are used as nasal decongestants in various non-prescription and prescription cold, sinus, and allergy products. The company has six additional opioid products in various stages of formulation development. Acura Pharmaceuticals, Inc. has collaboration and license agreements with Egalet US, Inc.; and Egalet Ltd. to manufacture and commercialize Oxaydo products worldwide; and development and commercialization agreement with Abuse Deterrent Pharma, LLC to develop LTX-03, an immediate-release tablets utilizing LIMITx technology. The company was founded in 1935 and is based in Palatine, Illinois.
Acura Pharmaceuticals, Inc.’s ISS Governance QualityScore as of N/A is N/A. The pillar scores are Audit: N/A; Board: N/A; Shareholder Rights: N/A; Compensation: N/A.